%0 Journal Article
%A Tomsitz, Dirk
%A Ruf, Theresa
%A Heppt, Markus
%A Staeger, Ramon
%A Ramelyte, Egle
%A Dummer, Reinhard
%A Garzarolli, Marlene
%A Meier, Friedegund
%A Meier, Eileen
%A Richly, Heike
%A Gromke, Tanja
%A Siveke, Jens
%A Franklin, Cindy
%A Klespe, Kai-Christian
%A Mauch, Cornelia
%A Kilian, Teresa
%A Seegräber, Marlene
%A Schilling, Bastian
%A French, Lars E.
%A Berking, Carola
%A Heinzerling, Lucie
%T Tebentafusp in Patients with Metastatic Uveal Melanoma: A Real-Life Retrospective Multicenter Study
%J Cancers
%V 15
%N 13
%@ 2072-6694
%C Basel
%I MDPI
%M DKFZ-2023-01436
%P 3430
%D 2023
%X Background: Tebentafusp has recently been approved for the treatment of metastatic uveal melanoma (mUM) after proving to have survival benefits in a first-line setting.Patients and methods: This retrospective, multicenter study analyzed the outcomes and safety of tebentafusp therapy in 78 patients with mUM.Results: Patients treated with tebentafusp had a median PFS of 3 months (95
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:37444540
%R 10.3390/cancers15133430
%U https://inrepo02.dkfz.de/record/277719